🔥85% Remission?! Can Aptevo 🚀 After Its Reverse Split? Trading Plan Revealed! скачать в хорошем качестве

🔥85% Remission?! Can Aptevo 🚀 After Its Reverse Split? Trading Plan Revealed!

Aptevo Therapeutics (NASDAQ: APVO) just stunned the biotech world with mipletamig's 85% remission rate in frontline AML patients—no dose-limiting toxicities, and massive investor buzz. But is the stock still a buy after a 1-for-20 reverse split and $12.1M emergency funding raise? In this video, we break down Aptevo’s recent clinical success, shaky financials, and explosive chart setup. Aptevo is a Seattle-based clinical-stage biotech company specializing in immuno-oncology therapies using its ADAPTIR and ADAPTIR-FLEX platforms. Its flagship candidate, mipletamig, targets acute myeloid leukemia (AML), and the firm is advancing a pipeline of bispecific antibodies aimed at various cancers. We’ll reveal a real-world trading strategy tailored to Aptevo’s current market setup—perfect for swing traders and investors navigating today’s high-volatility biotech landscape. 💥 What are the real risks? 💥 Where’s the next buying opportunity? 💥 How do you trade this without getting burned? Watch now to get the full picture and a practical trading plan to tackle this volatile mover! #BiotechStocks #CancerResearch #TradingStrategy #StockMarketNews #MemeStocks #APVO #Aptevo #NASDAQ #Immunotherapy #Oncology #ReverseSplit